Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.

Lakshmi Nayak,Chinmay Bhavsar,Phioanh Leia Nghiemphu,Myriam Bednarek Debruyne,Terri Armstrong,Patrick Y Wen,Justin T Jordan,Sarah C Gaffey,Jennifer Leigh Clarke,Thomas Joseph Kaley,Timothy Smith,Victoria Caruso,Katherine B Peters,Annette M Molinaro,John Frederick De Groot,Howard Colman,David A Reardon,Mariano Severgnini,Martin J Taphoorn

doi:10.1200/jco.2018.36.15_suppl.2037

Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.

Lakshmi Nayak, Chinmay Bhavsar + Show 17 more

https://doi.org/10.1200/jco.2018.36.15_suppl.2037

Copy DOI

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2018

Affiliation: Dana-Farber Cancer Institute, University of California, Los Angeles, National Cancer Institute, Dana-Farber Brigham Cancer Center, Harvard University, Massachusetts General Hospital, University of California, San Francisco, Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, Duke Medical Center, The University of Texas MD Anderson Cancer Center, Huntsman Cancer Institute, Medisch Centrum Haaglanden

#Neurologic Assessment In Neuro-oncology #Neurologic Function In Patients + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

2037Background: The neurologic assessment in neuro-oncology (NANO) scale was developed as a standardized metric to objectively measure neurologic function in patients (pts) with brain tumors to com...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.